Table 2.
Primary outcomea
| Characteristic | Primary cohort, No. (%) | EFR cohort, No. (%) | LFR cohort, No. (%) |
|---|---|---|---|
| Total No. | 2627 | 1586 | 2415 |
| Any BMA | 619 (23.6) | 643b (40.5) | 407 (16.9) |
| Denosumab | 306 (11.7) | 296 (18.7) | 212 (8.8) |
| Zoledronic acid | 325 (12.4) | 271 (171) | 203 (8.4) |
Receipt of BMAs within 180 days of diagnosis. Because some patients received both denosumab and zoledronic acid, the “Any BMA” total may be less than the sum of the 2 individual drugs. The EFR cohort comprised patients with a diagnosis of osteoporosis, osteopenia, or bone fracture before PCa diagnosis. The LFR cohort comprised the subset of the primary cohort that had no claims for osteoporosis, osteopenia, any SRE, or DEXA during the outcome period. BMA = bone modifying agent; DEXA = dual-energy x-ray absorptiometry; EFR = elevated fracture risk; LFR = lowest fracture risk; PCa = prostate cancer; SRE = skeletal-related event.
For the EFR cohort, “Any BMA” also includes 88 patients who received oral bisphosphonates because orally administered bisphosphonates are appropriate for osteoporotic fracture prevention, and this cohort contains patients with evidence of high osteoporotic fracture risk.